I don’t mind having my photo taken – triple checked and filtered for Instagram – but 70 cameras pointing at me while I’m down to my knickers is a bit daunting.
A robotic voice tells me to stay still and close my eyes as I stand in a huge curved scanner while classical music plays in the background.
With a flash of light, 2,000 photographs are taken of my body, in the hope of capturing every mark, freckle and mole to analyse for different skin cancers.
This full-body scan is happening at a sci-fi-style clinic in Manchester city centre, with me wearing a dressing gown and hexagon-shaped rubber slippers. The millions of data points collected will create a 3D avatar of my body using AI.
Over the past two years, the market for health MOTs has boomed, with people willing to pay hundreds, or even thousands, for them, and companies such as Prenuvo, Ezra and Neko Health raising millions in venture capital.
While Prenuvo and Ezra offer a whole-body MRI scan, I’ve opted for Neko Health, which doesn’t delve quite as deeply, and comes with a more modest £299 price tag. There are currently 100,000 people on its waiting list.
I will be screened for a range of different conditions, including skin cancer, cardiovascular disease, type 2 diabetes, eye conditions like glaucoma, as well as kidney and blood disorders.
I don’t have any symptoms, but what if they do find something? More on that later.
The body scan industry sees itself as a new frontier in healthcare, preventing disease before it has a chance to fully appear. But there is scepticism about how beneficial these scans really are for otherwise healthy patients.
My socials are inundated with videos of enthusiastic clients filming themselves in scan machines, getting their bloods taken and testing their grip strength.
Hjalmar Nilsonne, one of the founders of Neko Health, wants to see this preventative treatment available for every individual, not just those who can afford to pay for it.
“While medicine has progressed so much over the past century, primary care is still very basic. Why wait until we see symptoms?” Nilsonne says. “The data is super clear – prevention is preferable to cure.” READ MORE
by Ruth Clegg
Source: bbc.com
Taubert joined J&J’s executive committee in 2018 when she was elevated from leading the pharmaceuticals unit’s operations in the Americas to heading up the entire department, just as her predecessor Joaquin Duato moved up to become then-CEO Alex Gorsky’s right hand. She was named one of the Fiercest Women in Life Sciences in 2019.
BioNTech has named the head of Swedish pharmaceutical company Sobi to be its next CEO, marking the latest step of a transformation that will see the prominent messenger RNA drugmaker become more of an oncology specialist.
Argenx will pay $77 a share in cash, valuing the U.S. drug developer at about $2.2 billion, in a deal that gives it a first-in-class anti-CD122 antibody that has shown early promise in vitiligo and celiac disease.
